胆囊切除术后腹泻的研究进展

胆囊切除术后腹泻(PCD)是胆囊切除术后综合征(PCS)的常见症状之一,不仅发病率高,且严重影响患者的工作和生活。因此,PCD的治疗已逐渐成为研究热点。然而,目前PCD的发病机制及其治疗方法尚不明确。本文就PCD的相关流行病学、病理生理、发病机制及治疗策略等方面进行综述。     

胸痛特征诊断冠心病的准确性

目的 探讨胸痛特征诊断冠心病的准确性.方法 连续入组2012年6月至2016年6月经过冠状动脉造影(CAG)和冠状动脉血流储备分数(FFR)检查的住院患者240例,根据临床病史的描述将患者分成无胸痛组(55例),不典型胸痛组(79例),典型劳力心绞痛组(64例)和支架植入组(42例).将不同胸痛性质与CAG和FFR进行...     

The effects of desipramine, zimelidine, electroconvulsive treatment and lithium on rat brain biogenic amines: a comparison with peripheral changes

The effects of 4 common treatments for affective disorders on total body norepinephrine (NE) and dopamine (DA) turnover and metabolism were evaluated in rats. The treatments were chronic desipramine (DMI), zimelidine (ZMI), electroconvulsion (ECT) and lithium (Li). The central effects of ECT and Li were also assessed in the brain. The results obtained were compared with the effects of these 4 treatments on total NE (Sum NE) and DA (Sum DA) turnover in depressed patients. We have also evaluated central and/or peripheral effects of these treatments on phenylethylamine, p-tyramine and serotonin metabolism. The urinary changes in Sum NE and DA observed after DMI, ZMI and Li in the rat were similar to those found in depressed patients; Sum NE was significantly reduced. In contrast to its effects on depressed patients, chronic ECT significantly increased Sum NE. Similar to depressed patients, ECT reduced the fraction of NE escaping re-uptake in the rat. Sum DA was not affected by DMI, ZMI or ECT, but was significantly reduced by chronic Li treatment. All 4 treatments significantly reduced serotonin metabolism as indicated by reduced 5-hydroxyindoleacetic acid excretion rates. DMI, ZMI and Li treatments significantly reduced phenylethylamine urinary but not p-tyramine urinary outputs. The opposite effect was observed after ECT. Consistent with their effects on Sum NE, Li reduced while ECT increased hypothalamic NE turnover as deduced from the changes in 3-methoxy-4-hydroxyphenylglycol's rate of formation. As for Sum DA, Li had no effect on 3,4-dihydroxyphenylacetic acid or homovanillic acid's rates of formation in the caudate nucleus. Chronic ECT produced a small, but significant increase in homovanillic acid's rate of formation in the caudate nucleus.     

Solitary cavities of the lung: diagnostic implications of cavity wall thickness

Sixty-five solitary cavities of the lung were evaluated for wall thickness. All lesions in which the thickest part of the cavity wall was 1 mm were benign. Of the lesions whose thickest measurement was 4 mm or less, 92% were benign. Of cavities that were 5-15 mm in their thickest part, 51% were benign and 49% malignant. Of those over 15 mm thick, 95% were malignant. Measurement of the thickest part of te cavity wall gives a more reliable indication of benignancy or malignancy than measurement of the thinnest part.     

Single-Incision Laparoscopic Common Bile Duct Exploration with Conventional Instruments: an Innovative Technique and a Comparative Study

Background

Single-incision laparoscopic surgery developed rapidly in recent years. We introduce an innovative technique: single-incision laparoscopic common bile duct exploration (SILCBDE) with conventional instruments. A retrospective comparison between SILCBDE and standard laparoscopic common bile duct exploration (LCBDE) was analyzed.

Methods

Thirty-four patients who underwent LCBDE for choledocholithiasis in a period of 17 months were enrolled. Seventeen standard LCBDEs and 17 SILCBDEs were attempted. Simultaneous cholecystectomies were performed.

Results

The stone clearance rate was 94.1 % (16 patients) in the standard LCBDE group and 100 % in the SILCBDE group. There was no statistical difference in demographic distribution, clinical presentations, and operative results between the two groups, except the SILCBDE group had a higher rate of acute cholecystitis than the standard LCBDE group (76.5 vs. 35.3 %; p?<?0.05). One procedure (5.9 %) in the SILCBDE group was converted to a four-incision transcystic LCBDE. The complication rate was 11.8 % (two patients) in the standard LCBDE group and 5.9 % (one patient) in the SILCBDE group. The average follow-up period was 4.2 months.

Conclusion

SILCBDE is as safe and efficacious as standard LCBDE in experienced hands. Choledochoscope manipulation and bile duct repair are the key skills. Long-term follow-up and further prospective randomized trials are anticipated.     

The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan

Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (NalFL) comprises the current standard for gemcitabine-failed metastatic pancreatic ductal adenocarcinoma (PDAC). As liposomes generally accumulate in the spleen, we evaluated the impact of spleen volume on prognosis. We enrolled patients with metastatic PDAC who failed gemcitabine-based therapy and were initiated on NalFL between August 2018 and November 2020. The spleen volume before NalFL administration was evaluated. They were stratified into dose subgroups (i.e. low, < 48 mg/m²; intermediate, 48 - < 64 mg/m²; high, ≥ 64 mg/m²) by the average nal-IRI dose during the entire treatment, and multivariate analysis of overall survival (OS) was performed. We included 547 patients with a median age of 63 years (range, 27-89 years) and a median of 1 (range, 0-7) palliative chemotherapy regimen. The median spleen volume was 245 mL (range, 82-817 mL). Among patients with splenomegaly (≥ 245 mL), the low-dose subgroup had the worst median time to treatment failure (TTF, 1.8 months vs. 2.5 months vs. 2.5 months, P = 0.020) and OS (3.3 months vs. 5.9 months vs. 6.6 months, P = 0.018) as against no prognostic impact in patients without splenomegaly. In the multivariate analysis of patients with splenomegaly, performance status (PS) ≥ 2, body surface area (BSA) < 1.6 m², prior fluoropyrimidine use, liver metastasis, and low-dose subgroup were independent poor prognostic factors. A low average nal-IRI dose was significantly associated with poor prognosis, especially among patients with splenomegaly. Further pharmacological studies should validate the relevance of spleen volume on the treatment outcomes of nal-IRI.     

Ferumoxide标记Flk1＋＋CD31＋-CD34-人骨髓间充质干细胞及其在食蟹猴脑内移植示踪观察

目的探讨Ferumoxide-PLL标记Flk1 CD31-CD34-人骨髓间充质干细胞(hBMSC)的方法及其在食蟹猴脑实质内移植活体示踪的可行性。方法采用Ferumoxide-PLL标记hBMSC,台盼蓝染色、普鲁士蓝染色和透射电镜扫描鉴定标记效率及细胞活力。体外磁共振成像(MRI)分别扫描标记和未标记细胞,计算T2*的弛豫时间和弛豫率(R2*)变化。通过立体定向手术将标记的hBMSC移植入食蟹猴右侧基底节区,采用MRI扫描活体示踪细胞。采用免疫组织化学、普鲁士蓝和HE染色对脑组织切片进行干细胞存活、分化及病理学研究。结果Ferumoxide-PLL标记hBMSC效率为96%,普鲁士蓝染色、电镜可显示标记hBMSC细胞质内铁颗粒。1×106和5×105两组Ferumoxide-PLL标记细胞的T2*的弛豫时间分别为68.86和79.88ms,而未标记细胞分别为12.71和15.24ms。标记细胞的R2*分别为78.68和65.61/s,分别是未标记细胞(14.52和12.52/s)的5.4和5.2倍。移植后3周MRI扫描T2WI仍可发现hBMSC呈明显的低信号。病理及免疫荧光结果显示hBMSCs在移植区大量存活,移植区有大量新生血管,但未见hBMSC向神经细胞分化。结论Ferumoxide-PLL可高效标记hBMSC,能显著增加其MRI图像对比度。MRI可活体示踪干细胞。移植入食蟹猴脑内的hBMSC可大量存活并促进新生血管形成。     

微创经皮肾镜碎石术治疗直径≤2 cm肾结石的 临床研究

目的 探究微创经皮肾镜碎石术治疗直径≤2 cm肾结石的临床疗效和安全性.方法 方便选取中国人民解放军第八二医院和淮安市淮阴医院泌尿外科2013年12月—2016年12月收治的60例肾结石患者按照手术方式不同分为观察组(n=38)和对照组(n=22)进行回顾性分析,观察组患者采用微创经皮肾镜碎石术治疗,对照组采用传统的开放式手术治疗,比较两组患者手术时间、术中出血量、住院时间、结石清除率和术后并发症发生情况.结果 观察组手术时间、 术中出血量和住院时间显著优于对照组[(48.66±13.12)min vs(110.23±24.88)min;(66.44±25.57)mL vs(128.58±42.55)mL;(6.17±1.11)d vs(12.65±3.54)d],差异有统计学意义(t=12.5767,P=0.0000;t=7.0823,P=0.0000;t=10.4836,P=0.0000);观察组结石清除率(94.73%)显著高于对照组(77.27%),差异有统计学意义(X2=4.1236,P=0.0423);观察组术后并发症产生率(7.89%)显著低于对照组(36.36%),差异有统计学意义(X2=7.5424,P=0.0060).结论 微创经皮肾镜碎石术治疗直径≤2 cm肾结石手术时间短,术中出血少,住院时间短,结石清除效果好,术后并发症少,值得在临床上广泛推广.     

Neuroprotective action of lithium in disorders of the central nervous system

Substantial in vitro and in vivo evidence of neurotrophic and neuroprotective effects of lithium suggests that it may also have considerable potential for the treatment of neurodegenerative conditions.Lithium's main mechanisms of action appear to stem from its ability to inhibit glycogen synthase kinase-3 activity and also to induce signaling mediated by brain-derived neurotrophic factor.This in turn alters a wide variety of downstream effectors,with the ultimate effect of enhancing pathways to cell surviva...